Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No

Feb 11 2014

• By Cathy Dombrowski

Related Content

Can The Medicines Company Rebound From A Phase III Blow?

May 13 2009

Is TMS' Cangrelor A CHAMPION After All? "Noise On The Line" Confounded Endpoint Data, CEO Says

Nov 17 2009

The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing

Mar 11 2013

<em>Brilinta</em> Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge

Jan 01 2012

<em>Avandia</em> Review Endorsement Aided By Good Data, Cultural Shift On Safety

Jun 17 2013

Related Companies

The Medicines Company

Sanofi

Bristol Myers Squibb Company

Eli Lilly and Company

Daiichi Sankyo Co., Ltd.

AstraZeneca PLC

GSK plc

Additional Topics

United States Regulation Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window